Reply to Yang et al.: Tocilizumab treatment in COVID-19 patients needs the assessment of the disease severity and timely intervention

Affiliations

• ¹ Respiratory and Critical Care Medicine, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei 230000, People's Republic of China; ustcwhm@ustc.edu.cn xxlahh08@163.com.
• ² Respiratory and Critical Care Medicine, Anhui Fuyang Second People's Hospital, Fuyang 230000, People's Republic of China.
• ³ Respiratory and Critical Care Medicine, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei 230000, People's Republic of China.
• ⁴ Institute of Immunology and the Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei 230000, People's Republic of China.
• ⁵ Hefei National Laboratory for Physical Sciences at Microscale, University of Science and Technology of China, Hefei 230000, People's Republic of China.
• ⁶ Intensive Care Unit, The First Affiliated Hospital of University of Science and Technology of China (Anhui Provincial Hospital), Hefei 230000, People's Republic of China.
• ⁷ Hemodialysis Center, Anhui Fuyang Second People's Hospital, Fuyang 236000, People's Republic of China.
• ⁸ Institute of Immunology and the Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Disease, School of Life Science and Medical Center, University of Science and Technology of China, Hefei 230000, People's Republic of China; ustcwhm@ustc.edu.cn xxlahh08@163.com.